Your session is about to expire
← Back to Search
Amivantamab for Salivary Gland Cancer
Study Summary
This trial will test if amivantamab can shrink tumors in people with adenoid cystic carcinoma that has returned or spread.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My eye condition is stable.I am 18 years old or older.I have an ongoing heart condition.I do not have any active liver infections.I am not currently on any experimental drugs, or it has been 30 days since my last dose.I am not pregnant and will not breastfeed if treated.My cancer is confirmed as adenoid cystic carcinoma, not limited to salivary glands.My daily activity is not severely restricted by my health.My organs and bone marrow are working well.My brain scans show no cancer growth after treatment for brain metastases in the last month.I have previously used amivantamab.My cancer has returned or spread and cannot be cured with surgery or other treatments. It has also gotten worse in the last 6 months.I haven't had chemotherapy or immunotherapy in the last 4-6 weeks.I have recovered from previous cancer treatment side effects, except for hair loss or mild nerve pain.I can take care of myself but might not be able to do active work.My doctor agrees that my brain metastases don't need immediate treatment.I have been vaccinated for hepatitis B or have a low hepatitis B viral load.I have had hepatitis C but am now virus-free after treatment.I have severe heart failure or was hospitalized for it within the last 6 months.I have a rash from cancer immunotherapy that hasn't healed.I have or had lung inflammation not caused by an infection.I have another cancer type, but it won't affect this trial's treatment.I will use a condom during the study and for 6 months after, and if my partner can get pregnant, they will also use birth control.I haven't had major surgery or significant injury in the last 4 weeks, or if I did, I'm fully recovered.My cancer has returned or spread and cannot be cured with surgery or other treatments.
- Group 1: Amivantamab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this a new type of clinical trial?
"Since 2016, Amivantamab has been the focus of 9 different clinical studies. The first study was sponsored by Janssen Research & Development, LLC in 2016 and 780 people were recruited. Amivantamab received Phase 1 drug approval after this initial study. Currently, these 9 active studies are being conducted across 105 cities and 33 countries."
What are Amivantamab's primary therapeutic applications?
"Amivantamab can be used to treat patients that have received platinum based therapy, exons, and malignant neoplasms in the past."
What is the FDA's current stance on Amivantamab?
"Amivantamab's safety is based on preliminary data and falls in the 2 range."
Are new participants being recruited for this clinical trial at this time?
"This study, which is currently seeking patients, was originally posted on August 5th, 2022. The last edit to the listing was also made on that date."
Could you share how many people are taking part in this research?
"The clinical trial is recruiting patients, with 18 participants needed from 1 site. The original posting was on 8/5/2022, and there have been no updates since."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger